Zealand Pharma’s Post

Conventional understanding of the magnitude, intensity and productivity of R&D investment in the biopharmaceutical ecosystem is predominantly based on survey data from large, publicly listed biopharmaceutical companies. Here, authors present an analysis of global R&D investment and revenue in 2021 for the full range of companies in the biopharmaceutical ecosystem — public and private companies, at the development stage and commercial stage — using reported financial statement data and data on capital raises. https://lnkd.in/gYwhUxbf

Ligand’s Captisol technology platform has helped optimize the solubility and stability of drugs for some of the world’s leading biopharmaceutical companies including Merck Pfizer Amgen and Gilead Sciences. Today there are more than 15 Captisol-enabled™ products approved worldwide. The leaders of our Captisol team, Drs. Vince Antle and James Pipkin, recently sat down with Lawrence Business Magazine to discuss how this unique technology has changed how drugs are developed and formulated. Read the article here: https://bit.ly/4bRjJtv

ANI Pharmaceuticals, Inc., a diversified biopharmaceutical company, agreed to acquire Alimera, a global pharmaceutical company, for $453m. "We are pleased to have reached this agreement with ANI, which we believe recognizes the value we have created at Alimera and creates compelling value for our shareholders. ANI and Alimera share a common mission of putting patients first, and this complementary transaction creates a bigger platform to leverage our global infrastructure and outstanding team. I would like to thank Alimera employees, past and present, for always finding a way to help patients maintain better vision longer. We look forward to working with ANI to complete this transaction and help grow its presence in the ophthalmology segment," Rick Eiswirth, Alimera President and CEO. Alimera Sciences (led by Rick Eiswirth) is advised by Centerview Partners, Perella Weinberg, DLA Piper and CORE IR & PR (led by Scott Gordon). ANI Pharmaceuticals (led by Nikhil Lalwani) is advised by Guggenheim Partners, Raymond James, Hughes Hubbard & Reed LLP and In-Site Communications, Inc. (led by Lisa Wilson). #MergerAcquisitionsDiversitures #Markets #Pharmaceuticals

AstraZeneca has demonstrated remarkable growth, increasing its sales from $45 to $45.8 billion as 2023 came to a close. Under the guidance of Pascal Soriot, the company is targeting an ambitious $80 billion by 2030, supported by 20 drugs in the pipeline poised to reach the market!!🚀 The company's strategic focus on growth has been recognized by the market, with shares rising 1%, indicating investor confidence. AstraZeneca aims for an 8% annual growth rate, despite the challenges of expiring patents, positioning themselves competitively with pharmaceutical leaders like Roche and Merck. Their strong product portfolio, which included 12 blockbuster drugs last year, has bolstered their presence in oncology. In a world of constant flux, visionary leadership and relentless drive for innovation keep the lifelines of a company thriving. 🌟 #AstraZeneca #GrowthStrategy #Innovation

ANI Pharmaceuticals, Inc., a diversified biopharmaceutical company, completed the acquisition of Alimera Sciences, a global pharmaceutical company, for $453m. "We are pleased to have reached this agreement with ANI, which we believe recognizes the value we have created at Alimera and creates compelling value for our shareholders. ANI and Alimera share a common mission of putting patients first, and this complementary transaction creates a bigger platform to leverage our global infrastructure and outstanding team. I would like to thank Alimera employees, past and present, for always finding a way to help patients maintain better vision longer. We look forward to working with ANI to complete this transaction and help grow its presence in the ophthalmology segment," Rick Eiswirth, Alimera President and CEO. Alimera (led by Rick Eiswirth) was advised by Centerview Partners, Perella Weinberg, DLA Piper, Core IR (led by Scott Gordon) and Longacre Square Partners (led by Dan Zacchei). Financial advisors were advised by Ropes & Gray LLP. ANI Pharmaceuticals (led by Nikhil Lalwani) was advised by Guggenheim Partners, Raymond James, Hughes Hubbard & Reed LLP (led by Ken Lefkowitz), Pérez-Llorca (led by @Javier Gomez) and In-Site Communications, Inc. (led by Lisa Wilson). Link to the article in the comments. #MergersAcquisitionsDivestitures #Biotechnology #Pharmaceuticals

Full scope... full solution... fully appreciating and anticipating the expectations and needs of our customers. That's what KBI Biopharma is all about. Today marks a pivotal point in our corporate journey. We can now carry through the productivity and quality of our projects to the end point - in a streamlined fashion. #cdmo #endtoendsolutions #onestopshop #contractmanufacturing #processdevelopment #fillfinish #downstreamprocessing

Developments in the CDMO Space! The biopharmaceutical industry is evolving rapidly, and keeping up with leadership changes can offer valuable insights into the direction companies are heading. I found this article on recent executive shuffles at CDMOs from Bioprocess International to be particularly informative. #biopharma #leadership #CDMO #biotech

“Grünenthal continues US growth push with $250M acquisition of Valinor Pharma” Grünenthal have taken another step toward solidifying their position in the US market with their most recent acquisition of Valinor Pharma, a Chicago-based pharmaceutical company founded in 2021. This adds to Grünenthal's growing portfolio of recent acquisitions, with the company committing over $2 billion toward M&A activity since 2017. Valinor’s flagship product, Movantik, is an oral treatment for OIC in adults with chronic non-cancer pain. This purchase secures Grünenthal's commercial exclusivity over the drug everywhere except Canada. CEO Gabriel Baertschi had this to say on the announcement: “As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio. “The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal.” For more bi-weekly updates on the biggest happenings in the pharmaceutical industry, sign up to our newsletter in the link below! 🔬 #lifesciences #pharmaceuticals #biotechnology #underthemicroscope

📢 𝗕𝗶𝗴 𝗡𝗲𝘄𝘀 𝗶𝗻 𝗣𝗵𝗮𝗿𝗺𝗮 𝗣𝗿𝗶𝗺𝗮𝗿𝘆 𝗣𝗮𝗰𝗸𝗮𝗴𝗶𝗻𝗴 & 𝗗𝗿𝘂𝗴 𝗗𝗲𝗹𝗶𝘃𝗲𝗿𝘆! Adagia Partners has just acquired Technoflex, a global leader in intravenous (IV) drug delivery systems. This strategic move is set to accelerate innovation and growth in the pharmaceutical and biopharmaceutical sectors, with Technoflex continuing to develop high-quality, flexible solutions for injectable drugs. 💡 𝗪𝗵𝘆 𝗶𝘁 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: Technoflex’s expertise in IV bags and connectors is crucial for the safe administration of complex therapies, making this acquisition a significant development for the pharma industry. Discover the full story and explore how this partnership is set to shape the future of drug delivery solutions. 👇 #PharmaPackaging #Technoflex #DrugDelivery #IVTherapies #PharmaceuticalIndustry #Biopharma #AdagiaPartners #HealthcareInnovation #PharmaNews #PrimaryPackaging

The FTC and DOJ have increasingly focused on the impact that life sciences M&A could have on “nascent competition,” which is competition that might eventually exist between therapies already on the market and those in early-stage development. The Agencies have even gone so far as to oppose deals involving investigational therapies in as early as phase 1 clinical trials – which can be nearly a decade away from reaching the market, if at all. By continuing to pursue this approach, the Agencies are jeopardizing a vital pathway for biopharmaceutical companies to be able to bring early-stage therapies to patients. Read more: https://lnkd.in/e_Vdi-W9